Clinical Trials Logo

Clinical Trial Summary

The neoCARHP study was a randomized, open-label, multicenter, phase III, neoadjuvant trial. This study aimed to compare the efficacy and safety of docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) with docetaxel/trastuzumab/pertuzumab (THP) neoadjuvant setting for HER2-positive breast cancer. Patients will be randomized at a 1:1 ratio into TCHP or THP, respectively, and will be treated every 3 weeks before surgery.The primary endpoint was the percentage of pCR (ypT0/is, ypN0), which was defined as the absence of any residual invasive cancer in both the breast and axillary lymph nodes.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04858529
Study type Interventional
Source Guangdong Provincial People's Hospital
Status Not yet recruiting
Phase Phase 3
Start date April 30, 2021
Completion date April 30, 2025